AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Andrey A. Ivashchenko, Kirill Dmitriev, Natalia Vostokova, Valeria N. Azarova, Andrew A. Blinow, Alina N. Egorova, И. Г. Гордеев, Alexey P. Ilin, Рубен Карапетян, Dmitry V. Kravchenko, N. V. Lomakin, Elena A. Merkulova, Natalia A. Papazova, Е.П. Павликова, Nikolay Savchuk, E. N. Simakina, Tagir A. Sitdekov, Е. А. Smolyarchuk, Elena G. Tikhomolova, Elena V. Yakubova, Alexandre V. Ivachtchenko
Abstract
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.